Houston breeds biotechnology hot shots

Article Abstract:

Houston, TX is headquarters for several new biotechnology companies that are actively researching new products. Houston Biotechnology Inc, started by Dominic Man-Kit Lam and Jared M. Emery, is developing an immunotoxin to prevent the recurrence of cataracts; this product may earn the company $600 million a year. Other leading biotechnology firms include Triplex Pharmaceutical Co, which is concentrating on new therapeutics derived from triple-helix-forming oligonucleotide compounds, and LifeCell Corp, which plans to market a new method for freeze-drying cells and tissues.

Commercial physical research, Product development, Cover Story, Houston, Texas, Encysive Pharmaceuticals Inc., Houston Biotechnology Inc., Triplex Pharmaceuticals Corp., LifeCell Corp., Tanox Inc.

---

If biological diversity has a price, who sets it and who should benefit?

Article Abstract:

An agreement signed in 1991 between the pharmaceutical firm Merck & Co, Inc, and the Instituto Nacional de Biodiversidad de Costa Rica (INBio) that combines commercial development with protection of biodiversity has become controversial. INBio, a private organization of Costa Rican scientists, gave Merck, the world's biggest drug company, the right to seek new drugs from Costa Rican plants and animals in exchange for support in protecting the country's native species. However, some Costa Ricans are accusing INBio of illegally auctioning off the country's natural riches.

Pharmaceutical industry, Contracts, Costa Rica, Environmental policy, Biological diversity conservation, Biodiversity conservation, Merck & Company Inc.

---

Amgen to spend $80 million to create Canadian institute

Article Abstract:

Amgen Inc is palnning to spend $80 million on a new medical research institute to be built in Toronto. Immunologist Tak Wah Mak of the Ontario Cancer Institute/Princess Margaret Hospital (OCI/PMH) will be the head of the new Amgen Institute. Links between the two establishments will continue and will further strengthen the cancer center through funding from Amgen. The latter will in turn gain the rights to pending patents of the institute.

Research, Investments, Cancer research, Cancer, Amgen Inc.

Similar abstracts:

• Abstracts: Comparative breeding ecology of Cooper's hawks in urban and exurban areas of southeastern Arizona. Cooper's hawks in urban and exurban areas: a reply
• Abstracts: The control of biological invasions in the world's oceans. Science, power, and system dynamics: The political economy of conservation biology
• Abstracts: Technology and tradition clash in India. Independence, but no Nobel winners for India since then. India goes to sea for research funds
• Abstracts: Apparent digestibility of amino acids in raw and heated conventional and low-trypsin-inhibitor soybeans for pigs
• Abstracts: Apparent digestibility of amino acids in raw and heated conventional and low-trypsin-inhibitor soybeans for pigs. part 2

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.